Meloxicam/rizatriptan

Last updated

Meloxicam/rizatriptan
Combination of
Meloxicam Nonsteroidal anti-inflammatory drug
Rizatriptan serotonin (5-HT) 1B/1D receptor agonist (triptan)
Clinical data
Trade names Symbravo
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. [1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan). [1] The ratio in Symbravo is 20 mg meloxicam to 10 mg rizatriptan. It is taken by mouth. [1]

Contents

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025. [2]

Medical uses

Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults. [1] [3]

Society and culture

Meloxicam/rizatriptan was approved for medical use in the United States in January 2025. [2]

References

  1. 1 2 3 4 5 "SYMBRAVO (meloxicam and rizatriptan) tablets, for oral use" (PDF). Axsome Therapeutics, Inc. U.S. Food and Drug Administration.
  2. 1 2 "Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" (Press release). Axsome Therapeutics. 30 January 2025. Retrieved 7 February 2025– via GlobeNewswire.
  3. ↑ Karsan N, Goadsby PJ (September 2022). "New Oral Drugs for Migraine". CNS Drugs. 36 (9): 933–949. doi:10.1007/s40263-022-00948-8. PMC   9477894 . PMID   36031682.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.